Overall survival (OS) outcomes from NRG-GY004, a phase III study comparing single-agent olaparib or combination cediranib and olaparib to platinum (Plat) based chemotherapy in recurrent plat sensitive ovarian cancer (OvCa) Meeting Abstract
| Authors: | Liu, J. F.; Brady, M.; Matulonis, U. A.; Miller, A.; Kohn, E. C.; Swisher, E.; Tew, W.; Cloven, N.; Muller, C.; Bender, D.; Moore, R.; Michelin, D.; Waggoner, S.; Geller, M.; Fujiwara, K.; D'Andre, S.; Carney, M.; Secord, A. A.; Walker, J.; Bookman, M. A. |
| Abstract Title: | Overall survival (OS) outcomes from NRG-GY004, a phase III study comparing single-agent olaparib or combination cediranib and olaparib to platinum (Plat) based chemotherapy in recurrent plat sensitive ovarian cancer (OvCa) |
| Meeting Title: | ESMO Congress 2023 |
| Journal Title: | Annals of Oncology |
| Volume: | 34 |
| Issue: | Suppl. 2 |
| Meeting Dates: | 2023 Oct 20-24 |
| Meeting Location: | Madrid, Spain |
| ISSN: | 0923-7534 |
| Publisher: | Oxford University Press |
| Date Published: | 2023-10-01 |
| Start Page: | S1285 |
| Language: | English |
| ACCESSION: | WOS:001087480203525 |
| DOI: | 10.1016/j.annonc.2023.10.039 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract: LBA45 -- Source: Wos |
